ADAM10 gene expression in the blood cells of Alzheimer's disease patients and mild cognitive impairment subjects

• Published in: Biomarkers Vol. 20; no. 3; pp. 196 - 201
• Main Authors: Manzine, Patricia Regina, Marcello, Elena, Borroni, Barbara, Kamphuis, Willem, Hol, Elly, Padovani, Alessandro, Nascimento, Carla Crispim, de Godoy Bueno, Patricia, Assis Carvalho Vale, Francisco, Iost Pavarini, Sofia Cristina, Di Luca, Monica, Cominetti, Márcia Regina
• Format: Journal Article
• Language: English
• Published: England Informa Healthcare 03.04.2015
• Subjects: ADAM Proteins - blood; ADAM Proteins - genetics; ADAM10 Protein; Aged; Aged, 80 and over; Aging; Alzheimer Disease - blood; Alzheimer Disease - genetics; Alzheimer Disease - physiopathology; Amyloid Precursor Protein Secretases - blood; Amyloid Precursor Protein Secretases - genetics; biomarkers; Biomarkers - blood; blood; Blood Platelets - metabolism; Blood Platelets - pathology; Case-Control Studies; Cognitive Dysfunction - blood; Cognitive Dysfunction - genetics; Cognitive Dysfunction - physiopathology; Female; Gene Expression; Humans; Male; Membrane Proteins - blood; Membrane Proteins - genetics; Middle Aged; Neuropsychological Tests; platelets; RNA, Messenger - blood; RNA, Messenger - genetics; Aging; blood; biomarkers; platelets
• ISSN: 1354-750X; 1366-5804
• DOI: 10.3109/1354750X.2015.1062554

ADAM10 is a potential biomarker for Alzheimer's disease (AD). ADAM10 protein levels are reduced in platelets of AD patients. The aim was to verify the total blood and platelet ADAM10 gene expression in AD patients and to compare with mild cognitive impairment (MCI) and healthy subjects. No significant differences in ADAM10 gene expression were observed. Therefore, the decrease of ADAM10 protein in platelets of AD patients is not caused by a reduction in ADAM10 mRNA. Further studies must be performed to investigate other pathways in the down regulation of ADAM10 protein.